Efficacy of Topical Cyclosporine A for Treatment and Prevention of Graft Rejection in Corneal Grafts With Previous Rejection Episodes

Shahid Beheshti University of Medical Sciences

Overview

The use of topical Cyclosporine A early after an episode of endothelial graft rejection after penetrating keratoplasty and continuing its administration for 6 months can reduce the course of that episode and recurrence of the rejection.

Study Type

INTERVENTIONAL

Conditions

Endothelial Graft Rejection

Interventions

SandimmuneDRUG

ArteloseDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Penetrating keratoplasty in eyes without vascularization Exclusion Criteria: * History of previous intraocular surgery

Locations (2)

Ophthalmic Research Center

Tehran, Tehran Province, Iran

Ophthalmic Research Center

Tehran, Tehran Province, Iran

Outcomes

Primary Outcomes

The rate of rejection after drop sessation

Time frame: 3 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.